The Current Development of Glycoconjugate Vaccines for Infectious Diseases

Dear Colleagues,

Glycoconjugate vaccines were successful against H. influenzae b (Hib) in the 1980s, leading to the development of other conjugate vaccines. However, chemical conjugation has limitations such as variability, high costs, and low recovery. Identifying alternative carrier proteins or systems is desirable. Biological conjugation, such as glycoengineering of recombinant vaccines in bacteria, bypasses these issues. Another alternative method is using Multiple Antigen Presenting Systems (MAPS) to produce glycoconjugate vaccines. This special issue highlights recent scientific knowledge and progress in the field of conjugate vaccines.

In this special issue on conjugate vaccines, we invite you to contribute an original report, observation, or review. Your contribution should focus on the development and evaluation of conjugate vaccines against infectious diseases, novel carrier proteins, recent advances in production technologies, and improvements in characterization methods. Specifically,

1. development and evaluation of conjugate vaccines against infectious diseases,
2. novel carrier proteins,
3. recent advances in novel technologies for conjugate vaccine production,
4. improvements in methods for conjugate vaccine characterization.

Dr. Fatme Mawas
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• bacterial vaccines
• polysaccharides
• conjugate vaccines
• carrier proteins